Dual-energy CT combined with nasopharyngeal endoscopy to detect nasopharyngeal carcinoma
Official title: Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma
Run by Zhongshan People's Hospital, Guangdong, China · NCT05884983 · Data updated 2026-11-12
This project will test whether doing dual-energy CT first and then nasopharyngeal endoscopy can better find nasopharyngeal carcinoma in adults who have high EBV-related blood markers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 30 Years to 69 Years |
| Sex | All |
| Enrollment | 12000 (estimated) |
| Sponsor | Zhongshan People's Hospital, Guangdong, China Academic / other |
| Locations | 1 site (Zhongshan, Guangdong) |
| Status | Recruiting |
| Started | February 1, 2023 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | August 15, 2025 |
| Trial ID | NCT05884983 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are residents of Zhongshan City without a prior diagnosis of nasopharyngeal carcinoma who can give informed consent, are in stable health, have high EBV serologic risk, and have no contraindications to contrast CT or endoscopy.
✕Probably not a fit
Patients with contrast media allergy, contraindications to nasopharyngeal endoscopy, severe cardiovascular/liver/kidney disease, or low EBV serologic risk are unlikely to receive benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants are screened with EBV-related blood tests (EBNA1-IgA, VCA-IgA, and BNLF2b/P85-Ab) and those with high serologic risk are selected for imaging. Selected participants undergo dual-energy CT first to record suspected nasopharyngeal lesions, followed by nasopharyngeal endoscopy to document visually suspicious areas. Biopsies are then taken from lesion sites indicated by CT and from suspicious sites found by endoscopy to obtain pathological confirmation. The study is observational and performed at Zhongshan People's Hospital in Zhongshan, Guangdong.
Why it matters
Potential benefit: If successful, this approach could lead to earlier and more accurate detection of nasopharyngeal carcinoma by combining targeted imaging with endoscopic biopsy.
How similar studies have gone: EBV serology and endoscopic biopsy are established tools for NPC detection and dual-energy CT has shown promise for lesion characterization, but the specific combination and sequencing used here is not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject residents in Zhongshan City * Subject has no medical record of nasopharyngeal carcinoma * Subject is able to comprehend, sign, and date the written informed consent document to participate in the study * Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study Exclusion Criteria: * Subject has heavy cardiovascular, liver or kidney disease * Subject has contraindications to nasopharyngeal endoscopy * Subject has contrast media allergy
Where it's running
-
Zhongshan People's Hospital
Zhongshan, Guangdong, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Docetaxel and SX-682 in head and neck cancers and prostate cancer
This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.
-
Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors
This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.
-
Induction and maintenance with MRG003, Tislelizumab, and Capecitabine for locally recurrent nasopharyngeal cancer
This study tests a treatment combo of MRG003 and a PD-1 blocker first, then continues with Capecitabine plus the PD-1 blocker to see if it helps patients with locally recurrent NPC.
-
Lower-dose (40.2 Gy) versus standard-dose (49.2 Gy) radiotherapy to low‑risk areas for chemosensitive Stage II nasopharyngeal cancer
This trial will try a lower radiotherapy dose (40.2 Gy) instead of the standard 49.2 Gy for people with stage II nasopharyngeal cancer who had a strong response to induction chemo and have undetectable EBV DNA.
-
Screening for early nasopharyngeal (nose) cancer
This project tests whether blood and saliva markers can find nasopharyngeal cancer early in adults aged 35 to 60 who are at higher risk because of ethnicity or family history.
-
Proton versus photon radiation for nasopharyngeal cancer
This trial will test whether proton radiation works at least as well as standard photon radiation for adults newly diagnosed with nasopharyngeal cancer that has not spread.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.